The Efficacy and Safety of N-acetylcysteine and Taurine (Nefrosave®) in Chronic Kidney Disease: A Double-Blind, Multicenter, Placebo-Controlled Trial (DELAY-CKD).

In contrast, participants treated with placebo+SOC showed an increase in uACR by 159.55% (99.88 μg/mg) with p-value approaching significance (p=0.079), again emphasizing the beneficial outcome when NAC+taurine was supplemented to SOC (Table 2 , Figure 2 ).

also in 1,608 other papers